Buy Braxia Scientific Before the Psychedelic Craze

Move over pot stocks, here comes the next group of “mind-bending” companies. Psychedelic stocks are picking up momentum after the FDA hinted at the approval of a brand-new treatment fad. Psilocybin, a naturally occurring psychedelic drug compound found most commonly in mushrooms, has been shown to help with depression, anxiety, OCD, PTSD, and even addiction.

And though it’s been used for many years, the FDA called psilocybin a “breakthrough therapy” for severe depression last year. Breakthrough therapy status is granted to new treatments by the FDA. In this case, it led to a US-based clinical trial with over 80 participants.

The results, according to the nonprofit Usona Institute, were very positive. Many experts believe it’s only a matter of time until full psilocybin approval is reached for medical use.

“As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psychedelics is changing – 2021 will be the time that psychedelic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative,” said Dr. Robin Carhart-Harris, a scientific advisor at Osmind.

Other studies reported similar outcomes as the one conducted by Usona.

“[Psilocybin] worked better than the usual antidepressant medications,” explained researchers at JAMA Psychiatry in a note.

New York University trials also concluded that “psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased cancer-related demoralization and hopelessness, and improved spiritual well-being.”

The Beckley Foundation said, “Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.”

With so much excitement revolving around psychedelics on the research side, it’s somewhat surprising to see that investors have yet to catch on. Most of the industry’s stocks are under $500 million in total market capitalization. Even the biggest companies are all worth less than $2 billion.

And though that makes investing in them riskier, it also suggests that there’s major untapped potential. Thankfully, a few stocks stand above the rest, meaning that if you do choose to take a shot on “shroom stocks,” you can at least tip the odds slightly more in your favor by making higher potential picks.

MindMed Inc. (NASDAQ: MNMD)
As one of the “big dogs” on the psilocybin block, MindMed is arguably the safest one to buy. You can think of MNMD as the Canopy Growth Corp of the psychedelics industry. It’s branching out to LSD studies, too, which have shown benefits in relation to anxiety, pain, and adult ADHD. The anxiety and ADHD treatment markets are estimated to be worth roughly $4.7 billion and $9.5 billion, respectively.

“These are still very early innings for us,” said MindMed’s co-founder and CEO JR Rahn in April after his company’s Nasdaq listing.

“The entire psychedelics industry is growing up. We’re accessing a whole new fresh set of investors that haven’t been able to access us before. I think that’s going to include sovereign wealth funds, pension funds, and further retail investors.”

2. Compass Pathways (NASDAQ: CMPS)

As another large psychedelic stock (relatively speaking), Compass Pathways offers investors a strong position in the depression treatment industry. CMPS highlighted a passage from the New England Journal of Medicine in a recent company press release:

“Positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).”

If CMPS experiences further success in this area, it would enter an industry that treats roughly 320 million patients spanning the globe.

3. Braxia Scientific Corp. (OTC: BRAXF)

Of the three stocks listed, Braxia is by far the smallest. That doesn’t mean, however, it has any less “punching power” than the other two. BRAXF develops psilocybin and ketamine products and, unlike many other companies in the industry, is actually using its products to treat conditions through the Canadian Rapid Treatment Center of Excellence, a Braxia subsidiary.

And because BRAXF has yet to be listed on the Nasdaq, it offers a huge potential value for investors. BRAXF shares are currently trading near their all-time low – a level of key support that has yet to be surpassed since the company went public. For moonshot-seeking speculators, that makes BRAXF a “can’t-miss” psychedelic trade.